Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
2.
Front Immunol ; 12: 586195, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33737924

RESUMO

Introduction: Burn injury is associated with a high risk of death. Whether a pattern of immune and inflammatory responses after burn is associated with outcome is unknown. The aim of this study was to explore the association between systemic immune and inflammatory responses and outcome in severely-ill burn patients. Materials and Methods: Innate immunity, adaptive immunity, activation and stress and inflammation biomarkers were collected at admission and days 2, 7, 14, and 28 in severely-ill adult burn patients. Primary endpoint was mortality at day 90, secondary endpoint was secondary infections. Healthy donors (HD) served as controls. Multiple Factorial Analysis (MFA) was used to identify patterns of immune response. Results: 50 patients were included. Age was 49.2 (44.2-54.2) years, total burn body surface area was 38.0% (32.7-43.3). Burn injury showed an upregulation of adaptive immunity and activation biomarkers and a down regulation of innate immunity and stress/inflammation biomarkers. High interleukin-10 (IL-10) at admission was associated with risk of death. However, no cluster of immune/inflammatory biomarkers at early timepoints was associated with mortality. HLA-DR molecules on monocytes at admission were associated with bacterial infections and septic shock. Later altered immune/inflammatory responses in patients who died may had been driven by the development of septic shock. Conclusion: Burn injury induced an early and profound upregulation of adaptive immunity and activation biomarkers and a down regulation of innate immunity and stress/inflammation biomarkers. Immune and inflammatory responses were associated with bacterial infection and septic shock. Absence of immune recovery patterns was associated with poor prognosis.


Assuntos
Infecções Bacterianas/etiologia , Queimaduras/complicações , Queimaduras/imunologia , Suscetibilidade a Doenças/imunologia , Choque Séptico/etiologia , Adulto , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/mortalidade , Infecções Bacterianas/terapia , Biomarcadores , Queimaduras/etiologia , Queimaduras/terapia , Comorbidade , Citocinas/metabolismo , Feminino , Humanos , Hospedeiro Imunocomprometido , Imunofenotipagem , Masculino , Pessoa de Meia-Idade , Mortalidade , Choque Séptico/diagnóstico , Choque Séptico/mortalidade , Choque Séptico/terapia , Linfócitos T/imunologia , Linfócitos T/metabolismo
3.
Int Immunopharmacol ; 40: 466-473, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27728898

RESUMO

Metastatic melanoma is a rapidly spreading cancer whose prognosis remains poor although important therapy advances in recent years. Ipilimumab, an anti-CTLA-4 immunotherapy used in advanced melanoma, is an effective immunotherapy alone or combined with other agents but with few predictive biomarkers of response. Here, we sought to analyze the potential of S100B, MIA, soluble MICA, anti-MICA antibodies and LDH as serum biomarkers of response and survival in a cohort of 77 advanced melanoma patients subjected to ipilimumab. Lower levels of S100B, and LDH at baseline and at weeks 3 and 6 correlated to a better response and survival. After multivariate analysis LDH maintained its independence at baseline and week 6, whereas S100B might be a useful tool for anti-CTLA-4 treatment monitoring after the first two doses of ipilimumab (W6). In addition, higher sMICA serum levels at baseline were associated with less frequency of irAEs.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/uso terapêutico , Imunoterapia/métodos , L-Lactato Desidrogenase/sangue , Melanoma/diagnóstico , Subunidade beta da Proteína Ligante de Cálcio S100/sangue , Neoplasias Cutâneas/diagnóstico , Adulto , Idoso , Anticorpos/sangue , Biomarcadores Tumorais/sangue , Antígeno CTLA-4/imunologia , Estudos de Coortes , Feminino , Seguimentos , Antígenos de Histocompatibilidade Classe I/sangue , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Ipilimumab , Masculino , Melanoma/tratamento farmacológico , Melanoma/mortalidade , Pessoa de Meia-Idade , Monitorização Fisiológica/métodos , Estadiamento de Neoplasias , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/mortalidade , Análise de Sobrevida
4.
J Invest Dermatol ; 135(1): 247-257, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25158034

RESUMO

The diverse aspects of cutaneous T-cell lymphomas may impede the diagnosis of Sézary syndrome (SS) and mycosis fungoides (MF), in particular, at early stages of the disease. We defined the CD158k/KIR3DL2 molecule as a first positive cell surface marker for Sézary cells (SCs). Here, we designed an optimized flow cytometry gating strategy, allowing the definition of lymphocytes of different sizes and defects of cell surface markers. Quantification by cytomorphology, flow cytometry, or clonal evaluation, gave similar results at initial time points and during the evolution in a prospective study involving 64 consecutive cutaneous T-cell lymphoma or erythrodermic patients. We found that CD158k+ T cells and circulating CD4+ T cells from MF patients exhibited unexpected patterns of cell surface expression with a marked heterogeneity of circulating lymphocytes even at initial diagnosis. Taken together, our results show that a multistep gating of CD158k+ cells is reliable to assess tumor burden in case of SS and suggest that both circulating MF CD4+ T cells and CD158k+ T cells are not homogeneous distinct memory populations. Further phenotypic and functional characterizations of such subsets are needed to better understand the underlying molecular mechanisms leading to the development of these diseases.


Assuntos
Biomarcadores Tumorais/metabolismo , Linfoma Cutâneo de Células T/metabolismo , Micose Fungoide/metabolismo , Células Neoplásicas Circulantes/metabolismo , Receptores KIR2DL2/metabolismo , Síndrome de Sézary/diagnóstico , Idoso , Idoso de 80 Anos ou mais , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/farmacologia , Biomarcadores Tumorais/imunologia , Progressão da Doença , Seguimentos , Heterogeneidade Genética , Humanos , Memória Imunológica , Estudos Longitudinais , Subpopulações de Linfócitos/metabolismo , Pessoa de Meia-Idade , Estudos Prospectivos , Receptores KIR2DL2/imunologia , Síndrome de Sézary/metabolismo
5.
Clin Nucl Med ; 37(11): 1065-8, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22996235

RESUMO

PURPOSE: Our aims were to assess the feasibility of imaging hypoxia in cervical carcinoma with (18)F-fluoroerythronitroimidazole ((18)F-FETNIM) and to compare (18)F-FETNIM uptake with metabolic uptake of (18)F-FDG. PATIENTS AND METHODS: We included 16 patients with cervical carcinoma. After imaging with FDG, (18)F-FETNIM PET/CT was performed and tumor-to-muscle (T/M) ratio uptake was assessed. (18)F- FETNIM uptake was correlated to FDG uptake and osteopontin (OPN), a marker of hypoxia, and patients' outcomes. RESULTS: All tumors were detected by (18)F-FDG PET. (18)F-FETNIM T/M ratios ranged from 1.3 to 5.4. There was no significant correlation between (18)F-FETNIM and (18)F-FDG uptake. High (18)F-FETNIM uptake (T/M > 3.2) was associated with reduced progression-free survival (log-rank = 0.002) and overall survival (log-rank = 0.02). Osteopontin ranged from 39 to 662 µg/L (median, 102.5 µg/L). Patients with OPN greater than 144 µg/L had reduced progression-free survival compared with those with OPN less than 144 µg/L (log-rank = 0.03). We found no significant correlation between (18)F-FETNIM uptake and OPN blood levels. CONCLUSIONS: Our preliminary results showed that a high uptake of (18)F-FETNIM was associated with a worse progression-free and overall survival.


Assuntos
Hipóxia/diagnóstico por imagem , Imageamento Tridimensional , Imagem Multimodal , Nitroimidazóis , Tomografia por Emissão de Pósitrons , Tomografia Computadorizada por Raios X , Neoplasias do Colo do Útero/diagnóstico por imagem , Adulto , Idoso , Intervalo Livre de Doença , Feminino , Fluordesoxiglucose F18 , Humanos , Pessoa de Meia-Idade , Neoplasias do Colo do Útero/patologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa